According to the current analysis of Reports and Data, the global Pulmonary Arterial Hypertension Market was valued at USD 6.02 billion in 2018 and is expected to reach USD 9.27 billion by the year 2026, at a CAGR of 5.6%. Pulmonary arterial hypertension is caused by the rise in pulmonary arterial pressure, which leads to an increase in the workload on the right side of the heart, which progresses the symptoms of PAH (Pulmonary arterial hypertension). The rise in the geriatric population, with the decrease in the levels of immunity, boosts up the market.

The prevalence of disorders like (Cirrhosis), Chronic lung diseases like emphysema, Asthma, etc. is driving the worldwide pulmonary arterial hypertension market. Even though a person with PAH can survive for a long time without treatment, it is nevertheless important to do so since the increased strain on the right side of the heart might cause heart failure. The quality of life will increase with treatment. It is anticipated that bad habits including smoking, using tobacco, and drinking will increase the prevalence of pulmonary arterial hypertension and the need for therapy. World Health Organization (WHO) and the Centre for Disease Control and Prevention had suggested that there is a prevalence of PAH that reported 15 to 50 million cases per head. Rise in disease like asthma COPD and chronic lung disorder is expected to rise the PAH market growth. According to the Global Asthma Report 2018 about 1000 people worldwide die of asthma every day and it has affected more than 339 million people. The rise in health care awareness and an increase in medical expenditure is likely to boost the market.

Request Free Sample Copy @ https://www.reportsanddata.com/download-free-sample/2667

Further key findings from the report suggest

• On the basis of Pulmonary Arterial Hypertension product segment Prostacyclin and Prostacyclin Analogs are expected to boost the market as it functions to improve the vasodilation by preventing platelet activation, they are expected to rise with a CAGR of 5.8%.
• Endothelin Receptor Antagonists (ERAs) have been used in the treatment of PAH as is reduces the production of endothelin. Owing to the increase in the cases of PAH, it is likely to reach 5.5% CAGR in the forecast period.
• Cicletanine and riociguat are the newly developed therapy of drugs, which has generated more significance in these years as there acts as potent vasodilators that are beneficial for treating severe PAH.
• European marketing has given authorization to GSK to expand the indication for Volibris a treatment for pulmonary arterial hypertension, as it was found that the combination of ambrisentan and tadalafil reduced the risk of clinical failure in PAH.
• Histone Deacetylation Inhibition (HDAC) is the recent approach for treating PAH, HDAC contributes to pulmonary vascular hypertension, HDAC inhibitors like valproic acid, and suberoylanilide hydroxamic acid inhibits the action of HDAC and further leads to vasodilation.
• Cuff-less BP monitoring devices have revolutionized and are also available in now in smartphones and wearables for blood pressure monitoring, and it can be checked with the access of the internet, smartphone applications would help to trace the blood pressure by blood pressure telemonitoring.
• Advances in telemonitoring have led to the development of Ambulatory telemetry for hearth monitoring. The patient for monitoring wears this wireless device.Telemetry monitors have traditionally had been used to monitor one or two parameters. However, recent advancements have made it possible to monitor three or four parameters of the heart on an average. The patient just has to wear the device which allows continuous monitoring within the area of coverage.
• Calcium channel blockers are widely used in treating hypertension. North America held a major share of the calcium channel blocker market. The rise in the geriatric population and the prevalence of obesity are the major factors that are anticipated to drive the demand for calcium channel blockers during the forecast period.

Key Players covered in this report are

Actelion Pharmaceuticals Ltd(Switzerland), Novartis International AG (Switzerland), Gilead Sciences, Inc.(US), United Therapeutics Corporation(US), GlaxoSmithKline Plc. (GSK)(London), Pfizer Inc(US), Dong-A ST Co Ltd (South Korea), Bayer HealthCare(Germany), Merck Sharp Dohme Corp (US) and Arena P.

Product Outlook (Revenue in Million USD; 2016–2026)             

• Prostacyclin and Prostacyclin Analogs
• Soluble Guanylate Cyclase Stimulators
• Endothelin Receptor Antagonists (ERAs)
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Calcium Channel Blockers
• Others

Technology Outlook (Revenue in Million USD; 2016–2026)

• Cuff-less BP monitoring devices
• Ambulatory monitors 
• Novel technology smartphones and Bluetooth enabled telemonitoring
• Tele-monitoring

Application Outlook (Revenue in Million USD; 2016–2026)

• Early-stage Drug Candidates (Phase I Phase II)
• Late-stage Drug Candidates (Phase III Registration Phase

End-Use Outlook (Revenue in Million USD; 2016–2026)

• Hospital
• Clinic

Geographic Segment Covered in the Report:

The Pulmonary Arterial Hypertension report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.

• North America (USA and Canada)
• Europe (UK, Germany, France and the rest of Europe)
• Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region)
• Latin America (Brazil, Mexico, and the rest of Latin America)
• Middle East and Africa (GCC and rest of the Middle East and Africa)

Major Points covered in this report are as below:

• The Pulmonary Arterial Hypertension industry development trends and marketing channels are analyzed. The feasibility of new investment projects are assessed and overall research conclusions offered.

• With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

• Development policies and plans, manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.

• The Pulmonary Arterial Hypertension Market report provides key statistics on the market status of the Pulmonary Arterial Hypertension manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central South America, Brazil, Argentina, Rest of South America, Middle East Africa, Saudi Arabia, Turkey, Rest of Middle East Africa

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2667

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.

Get Explore Latest Research Report by Reports and Data:

Rehabilitation Robots Market @ https://www.reportsanddata.com/report-detail/rehabilitation-robots-market

Valley Fever Market @ https://www.reportsanddata.com/report-detail/valley-fever-market

Spinal Trauma Devices Market @ https://www.reportsanddata.com/report-detail/spinal-trauma-devices-market

Veterinary Diagnostic Imaging Market @ https://www.reportsanddata.com/report-detail/veterinary-diagnostic-imaging-market

http://www.google.co.za/url?sa=turl=https://www.reportsanddata.com/

http://images.google.co.za/url?sa=turl=https://www.reportsanddata.com/

http://maps.google.co.za/url?sa=turl=https://www.reportsanddata.com/

http://images.google.com.co/url?sa=turl=https://www.reportsanddata.com/

http://maps.google.com.co/url?sa=turl=https://www.reportsanddata.com/

http://www.google.com.co/url?sa=turl=https://www.reportsanddata.com/

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: [email protected]